AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Ascendis Pharma A/S Ordinary Share
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG007R7VP72
243.37▲ 0.38 (0.16%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
242.99
Day's Range
240.79 – 244.58
52-Week Range
188.07 – 282.15
Volume
570.3K
Avg Volume
861.8K
Share Statistics
Shares Outstanding
Employees
1,189
Exchange
XNAS
Listed
2026-04-20
Share count as of December 31, 2025

Ascendis Pharma A/S Ordinary Share (ASND) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Ascendis Pharma A/S Ordinary Share (ASND)
What is Ascendis Pharma A/S Ordinary Share's Market Cap?
Ascendis Pharma A/S Ordinary Share's Market Cap is $15.1B, based on as-reported figures from SEC (XBRL) filings.
What is Ascendis Pharma A/S Ordinary Share's Enterprise Value?
Ascendis Pharma A/S Ordinary Share's Enterprise Value is $15.3B, based on as-reported figures from SEC (XBRL) filings.
What is Ascendis Pharma A/S Ordinary Share's Price / Sales?
Ascendis Pharma A/S Ordinary Share's Price / Sales is 17.8×, based on as-reported figures from SEC (XBRL) filings.
What is Ascendis Pharma A/S Ordinary Share's EV / Revenue?
Ascendis Pharma A/S Ordinary Share's EV / Revenue is 18.1×, based on as-reported figures from SEC (XBRL) filings.
What is Ascendis Pharma A/S Ordinary Share's Revenue (TTM)?
Ascendis Pharma A/S Ordinary Share's Revenue (TTM) is $845.1M, based on as-reported figures from SEC (XBRL) filings.
What is Ascendis Pharma A/S Ordinary Share's Net Income (TTM)?
Ascendis Pharma A/S Ordinary Share's Net Income (TTM) is -$267.6M, based on as-reported figures from SEC (XBRL) filings.
What is Ascendis Pharma A/S Ordinary Share's Diluted EPS (TTM)?
Ascendis Pharma A/S Ordinary Share's Diluted EPS (TTM) is -4.32, based on as-reported figures from SEC (XBRL) filings.
What is Ascendis Pharma A/S Ordinary Share's Net Debt?
Ascendis Pharma A/S Ordinary Share's Net Debt is $233.1M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ASNDAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of EUR, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017
Profit or loss [abstract]
Revenue
Cost of sales
Gross profit
Research and development expenses
Selling, general, and administrative expenses
Operating profit/(loss)
Share of profit/(loss) of associates
Finance income
Finance expenses
Profit/(loss) before tax
Income taxes (expenses)
Net profit/(loss) for the year
Attributable to owners of the Company
Basic earnings/(loss) per share
Diluted earnings/(loss) per share
Statement of comprehensive income [abstract]
Net profit/(loss) for the year
Items that may be reclassified subsequently to profit or (loss):
Exchange differences on translating foreign operations
Other comprehensive income/(loss) for the year, net of tax
Total comprehensive income/(loss)
Attributable to owners of the Company